Biosimilar Launch Playbook: Hub, Copay & SP Strategy

Thesis

Biosimilar launches require fundamentally different hub/copay/SP strategies than innovator biologics. Lower WAC changes copay economics. Interchangeability status determines pharmacy-level substitution dynamics. Formulary wars — not clinical differentiation — determine commercial success. And the competitive layering of originator vs. multiple biosimilar access programs creates a uniquely adversarial market environment where hub services function as commercial weapons, not just patient support infrastructure.

Record 18 new biosimilars were approved in 2024, with 40+ expected through 2025-2027. Each launch creates competitive program layering that drives demand for sophisticated hub and copay vendor capabilities.

Interchangeability and Pharmacy Substitution

The Interchangeability Threshold

The FDA’s interchangeability designation determines whether a biosimilar can be substituted at the pharmacy level without prescriber intervention — the single most important commercial variable for a biosimilar launch:

Status	Pharmacy Substitution	Commercial Implication
Biosimilar only	No automatic substitution; prescriber must explicitly prescribe by product name	Market access depends entirely on formulary positioning and payer mandates; hub programs focus on prescriber education and switching support
Interchangeable	Pharmacist can substitute without prescriber approval (subject to state laws)	Opens retail pharmacy channel; enables PBM/payer-directed automatic switching; hub programs must defend against and facilitate switching

As of 2026, several biosimilars have achieved interchangeability designation, including adalimumab biosimilars (Cyltezo, Hadlima, Hyrimoz, SIMLANDI, YUFLYMA). SIMLANDI (Alvotech/Teva, February 2024) was the first interchangeable high-concentration, citrate-free Humira biosimilar — a meaningful distinction since the originator Humira shifted to high-concentration, citrate-free formulation in its later launch years. Yusimry (Coherus) and several other adalimumab biosimilars are approved but not designated interchangeable, which constrains pharmacy-level substitution. Interchangeability fundamentally changes channel strategy:

Interchangeable biosimilars can flow through retail pharmacy channels (PBM-adjudicated), reducing the need for specialty-only distribution
Non-interchangeable biosimilars remain in specialty pharmacy channels, requiring hub support for prescriber-directed switching

State Substitution Laws

Even with FDA interchangeability designation, state pharmacy practice acts govern substitution:

Most states allow pharmacist substitution for interchangeable biosimilars with prescriber notification
Some states require affirmative prescriber consent before substitution
Notification requirements and timeframes vary significantly

Hub programs for interchangeable biosimilars must track state-by-state substitution rules and design workflows accordingly.

Formulary Positioning Strategies

The Payer Decision Framework

PBMs and health plans position biosimilars through several formulary strategies:

Strategy	Description	Hub Implication
Preferred biosimilar	Biosimilar on preferred tier; originator on non-preferred or excluded	Hub must facilitate new starts on biosimilar and switching from originator
Fail-first / step-through	Patient must try biosimilar before originator is covered	Hub must manage step therapy documentation and coordinate with prescribers
Biosimilar mandate	Only the biosimilar is covered; originator excluded from formulary	Hub handles PA for exceptions; copay program defends originator patients
Therapeutic interchange	PBM/payer switches stable patients from originator to biosimilar at pharmacy level	Hub manages transition support, adverse event monitoring, patient education
Open access	Both originator and biosimilar available; copay differentials drive choice	Copay programs become the primary competitive lever

Originator Defense vs. Biosimilar Offense

The competitive dynamic creates a two-sided market for hub and copay services:

Originator defense strategy:

Aggressive copay programs that eliminate patient out-of-pocket differential ($0 copay cards)
“Loyalty” programs that incentivize patients to stay on the originator
Hub services that emphasize continuity of care and minimize switching motivation
Payer engagement to maintain formulary access alongside biosimilar

Biosimilar offense strategy:

Competitive copay programs matching or beating originator copay offers
Patient switching programs with clinical support for the transition
Hub services optimized for rapid onboarding and payer-directed switching
Value messaging: lower total cost at equivalent efficacy

Patient Switching Programs

Switching from Reference to Biosimilar

Patient switching is the central operational challenge for biosimilar hub programs:

Clinical considerations:

Immunogenicity monitoring during transition (especially for complex biologics like infliximab, rituximab)
Patient education on biosimilar equivalence (overcoming “nocebo” effect — negative expectations from switching)
Prescriber engagement to ensure comfort with switching protocols
Adverse event monitoring and reporting during transition period

Operational requirements:

Patient identification: Which current reference biologic patients are candidates for switching?
Outreach coordination: Who contacts the patient and prescriber — the hub, the pharmacy, or the health plan?
Transition logistics: Managing the changeover from reference to biosimilar in the dispensing workflow
Follow-up: Post-switch adherence monitoring and clinical outcomes tracking

Hub vendor requirements:

Patient segmentation capabilities (identify switch candidates by payer, prescriber, therapy duration)
Multi-channel outreach (patient education, prescriber notification, pharmacy coordination)
Adverse event capture and reporting during switching period
Real-time tracking of switch completion rates and outcomes

Copay Support Economics for Biosimilars

The Lower WAC Problem

Biosimilar copay economics differ fundamentally from innovator biologics:

Parameter	Innovator Biologic	Biosimilar
WAC	$5,000-$10,000/month	$3,000-$7,000/month (15-40% discount)
Patient copay (commercial)	$500-$2,000/month (before copay card)	$200-$1,000/month (before copay card)
Copay card value needed	$400-$1,500/month to reach $0 OOP	$150-$800/month to reach $0 OOP
Manufacturer copay spend/patient/year	$5,000-$15,000+	$2,000-$8,000
Net revenue per patient/year	$30,000-$80,000	$20,000-$50,000
Copay ROI	High (copay spend is 10-20% of net revenue)	Moderate (copay spend is 10-20% of lower net revenue)

Lower WAC means:

Lower patient OOP burden: Less copay assistance needed per patient, reducing program costs
Lower net revenue per patient: Reduces the economic justification for expensive hub programs
Copay card as competitive weapon: When originator offers $0 copay, biosimilar must match or undercut to avoid the “why would I switch for the same price?” dynamic
Accumulator/maximizer impact: Copay accumulators hit biosimilar programs harder in absolute terms because the lower WAC means manufacturer copay spend is a larger percentage of net revenue

Copay Card Design for Biosimilars

Biosimilar copay programs must be designed for competitive positioning, not just patient access:

$0 copay offers: Table stakes — both originators and biosimilars typically offer $0 OOP. The competitive question is program breadth (eligible populations, annual caps, plan type coverage).
Accumulator/maximizer navigation: Biosimilar manufacturers must decide whether to fund copay through accumulator/maximizer programs. The ROI calculation is tighter than for innovator biologics given lower net revenue per patient.
Payer alignment copay: Some biosimilar manufacturers design copay programs that specifically support payer-directed switching (covering the patient’s incremental cost during transition) rather than broad-based access.

Hub Services Needs for Biosimilars

Hub-Lite vs. Full-Service

Biosimilar hub programs are typically leaner than innovator specialty hub programs:

Component	Innovator Hub	Biosimilar Hub
Benefits verification	Full BI with payer-specific navigation	Streamlined BI (payer already committed to biosimilar)
Prior authorization	Complex PA submission and appeals	Simpler PA (biosimilar is preferred) or PA defense (biosimilar is non-preferred)
Financial assistance	Full copay card + PAP + foundation coordination	Copay card focused; limited PAP need
Clinical nurse support	Disease/therapy education, injection training, adherence	Switching support, injection device differences, adherence
Patient finding	Standard enrollment funnel	Targeted switching identification and outreach
Adherence programs	Comprehensive refill management	Focused on post-switch adherence monitoring
Typical program cost	$5-15M/year	$2-5M/year

When Full Hub Is Still Needed

Some biosimilar launches require full hub infrastructure:

Complex administration (infused biosimilars like infliximab, rituximab): Buy-and-bill reimbursement support, site-of-care coordination
First biosimilar in a category: Patient education and prescriber adoption support for a new competitive dynamic
Interchangeable with retail eligibility: Broader distribution creates more touchpoints requiring coordination
Competitive defense: When the originator runs a sophisticated hub, the biosimilar needs comparable infrastructure to compete for prescriber and patient mindshare

SP Channel Dynamics

Retail vs. Specialty Distribution

For biosimilars with interchangeability designation:

Channel	Applicability	Biosimilar Implication
Retail pharmacy	Interchangeable biosimilars eligible for pharmacy-level substitution	PBM-directed switching at point of sale; reduces need for specialty pharmacy
Specialty pharmacy	Non-interchangeable biosimilars; complex administration	Traditional SP channel; limited distribution possible
Mail-order	Self-administered biosimilars with stable dosing	PBM mail-order preferred; 90-day fills reduce per-dispense costs
Buy-and-bill	Physician-administered biosimilars (infusion)	Provider purchases and administers; ASP+6% reimbursement; 340B implications

The channel strategy decision has direct hub program implications:

Retail-eligible biosimilars may not need traditional hub enrollment — the PBM manages access at the pharmacy counter
Specialty-only biosimilars still require hub support for PA, copay, and adherence
Buy-and-bill biosimilars need reimbursement support teams (field reimbursement managers, coding/billing assistance)

Key Biosimilar Launch References

Reference Product	Biosimilar Activity	Hub/Copay Complexity
Adalimumab (Humira)	10+ biosimilars launched 2023-2025; most with interchangeability	Highest complexity — competitive copay wars, formulary battles, retail/specialty channel split
Bevacizumab (Avastin)	Multiple biosimilars available	Buy-and-bill channel; site-of-care dynamics; 340B implications
Trastuzumab (Herceptin)	Multiple biosimilars available	Infused oncology; treatment center switching protocols; outcomes tracking
Insulin	IRA-driven market restructuring; $35 Medicare cap	Retail-dominant; massive volume; copay dynamics fundamentally altered by IRA
Infliximab (Remicade)	Competitive biosimilar market established	Infusion center switching; buy-and-bill complexity; health system formulary decisions
Rituximab (Rituxan)	Multiple biosimilars available	Oncology + autoimmune indications; complex switching across indications

Vendor Selection for Biosimilar Launches

Hub Vendor Evaluation

For biosimilar-specific hub programs, evaluate vendors on:

Switching program experience: Has the vendor managed reference-to-biosimilar patient transitions?
Payer integration: Can the hub coordinate with PBM-directed switching programs?
Competitive intelligence: Does the hub platform track competitive program activity (originator copay offers, formulary changes)?
Flexible scope: Can the hub scale from hub-lite (basic BI + copay) to full-service based on competitive dynamics?
Cost efficiency: Biosimilar economics demand leaner hub operations; evaluate per-patient cost against lower net revenue

Copay Vendor Evaluation

Copay programs for biosimilars should be evaluated on:

Speed of copay card deployment: First-to-market with copay coverage matters in competitive launches
Accumulator/maximizer navigation: Sophisticated copay designs that protect against accumulator erosion
Competitive matching: Ability to adjust copay offers in real-time to match originator changes
Channel flexibility: Copay programs that work across retail, specialty, and mail channels

Implications and Outlook

For Hub Vendors

Biosimilar launches represent a growing but lower-revenue opportunity compared to innovator specialty drugs. Hub vendors should:

Develop biosimilar-specific program templates (lighter-weight than innovator programs)
Build switching program capabilities as a competitive differentiator
Price biosimilar programs to reflect lower per-patient economics
Position biosimilar hub expertise as a new specialty

For Copay Vendors

The biosimilar copay market is intensely competitive and demands rapid response capabilities. As 40+ biosimilars launch through 2027, copay administration for competitive launches (multiple biosimilars + originator in the same market) will become a high-volume, operationally demanding segment.

For Manufacturers

Biosimilar commercial success depends on formulary positioning, not clinical differentiation. Hub and copay programs are competitive weapons, not patient safety infrastructure — a fundamentally different purpose than innovator hub programs. Vendor selection should prioritize competitive agility and payer integration over clinical depth.

Cross-References

Biosimilars & Impact on Pharma Services — Market-level biosimilar impact on pharma services categories
Copay Accumulators and Maximizers — Accumulator economics in biosimilar copay programs
Formulary Management & Step Therapy — Formulary strategies driving biosimilar access
Buy-and-Bill Reimbursement Model — Channel dynamics for infused biosimilars
Gross-to-Net Dynamics — GTN implications of biosimilar pricing
Hub Services Market Analysis — Biosimilar complexity as a market growth driver

Analysis compiled April 2026. Biosimilar market data based on FDA approval records, industry analyst reports, and vendor disclosures. Pricing and copay estimates are directional ranges, not product-specific.